- Home
- / Arcus Biosciences
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Arcus Biosciences financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$16.4
2024-10-29
Market Capitalization
$1.5 B
2024-10-29
Revenue
$247 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.4M | 8.4M | 15.0M | 77.5M | 382.9M | 112.0M | 117.0M | 258.0M | 247.0M | |
| General and administrative expense | 3.9M | 7.6M | 13.6M | 25.2M | 42.4M | 72.3M | 104.0M | 117.0M | 120.0M | 110.0M |
| Operating expense total | 18.2M | 54.9M | 63.2M | 103.7M | 201.8M | 328.6M | 392.0M | 457.0M | 568.0M | 633.0M |
| Depreciation and amortization | 10.0M | |||||||||
| EBIT | (18.2M) | (53.4M) | (54.9M) | (88.7M) | (124.2M) | 54.2M | (280.0M) | (340.0M) | (330.0M) | (386.0M) |
| EBIT margin, % | -3782.1% | -656.8% | -591.4% | -160.3% | 14.2% | -250.0% | -290.6% | -127.9% | -156.3% | |
| Investment income | (886.0K) | (1.2M) | (613.0K) | |||||||
| Interest income | 212.0K | 359.0K | ||||||||
| Interest expense | 2.0M | 9.0M | ||||||||
| Pre tax profit | 54.6M | (266.0M) | (301.0M) | (282.0M) | (353.0M) | |||||
| Income tax expense | 1.8M | 1.0M | 6.0M | 1.0M | ||||||
| Net Income | (18.0M) | (53.1M) | (49.6M) | (84.7M) | (122.9M) | 52.8M | (267.0M) | (307.0M) | (283.0M) | (353.0M) |
| EPS | 0.7 | (3.7) | (4.1) | (3.1) | (3.3) |